The ongoing row over access in the U.K. to a Vertex Pharmaceuticals (VRTX) cystic fibrosis treatment has taken an unexpected twist, with a member of parliament challenging the government to issue a compulsory license so that a lower-cost version of the medicine could eventually become available.

In a statement, MP Bill Wiggins suggested the government pursue a so-called Crown Use license that could pave the way for an alternative supply of the Orkambi treatment, “because Vertex refused the largest ever financial offer the National Health Service has made in its entire history for this medicine.” And he noted the NHS offered approximately $650 million over five years for patient access.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • U.K. government and Vertex Pharmaceuticals

    Cfs die while we await your outcomes . fast tracked coffins..

    Triple drugs combo that will be out 2019 the uk should be in it to win it !!

    10 Per cent of cfs these drugs dont work so Vertex Pharmaceuticals needs more drugs on the market ..
    So why stop these drugs when also more advance drugs and gene mapping treatments should be next step and more tablets based items !

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy